Market Research Report
Global Atherosclerosis Therapeutics Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||905976|
|Published||Content info||136 Pages
Delivery time: 1-2 business days
|Global Atherosclerosis Therapeutics Market 2019-2023|
|Published: August 6, 2019||Content info: 136 Pages||
Atherosclerosis occurs due to the development of plaque inside the artery, which later hardens and becomes thick. This hardened plaque narrows the artery which decreases the blood supply to body parts. Technavio's atherosclerosis therapeutics market analysis considers sales from small molecules and biologics. Our analysis also considers the sales of atherosclerosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant share, and this trend is expected to continue over the forecast period. Factors such as the availability of a wide range of drugs for the treatment of atherosclerosis will play a significant role in the small molecule segment to maintain its market position. Also, our global atherosclerosis therapeutics market report also looks at factors such as increased risk factors of atherosclerosis, availability of advanced diagnostic methods and rising prevalence of hypercholesterolemia. However, uncertainties in the side-effects associated with atherosclerosis therapeutics, product recalls, and stringent regulatory environment may hamper the growth of the atherosclerosis therapeutics market over the forecast period.
The advanced diagnostic techniques employed for diagnosis of atherosclerosis have undergone significant improvements in terms of technology and high-definition picture quality and provide information about the presence, size, and the composition of the plaque. These advanced diagnostic methods will lead to the expansion of the global atherosclerosis therapeutics market at a CAGR of over 5% during the forecast period.
The current research on atherosclerosis focuses on evaluating new drug targets that have genetic and mechanistic links. Efforts in this area have revealed some new pro-atherosclerotic pathways and can significantly reduce the risk of atherosclerosis. Growing R&D effects in this area are expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global atherosclerosis therapeutics market during the forecast period 2019-2023, view our report.
With the presence of a few major players, the global atherosclerosis therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global atherosclerosis therapeutics manufacturers, that include AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi.
Also, the atherosclerosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.